ENA Respiratory – Weekly Recap

ENA Respiratory is the focus of this weekly summary of notable developments affecting the private respiratory therapeutics company. ENA Respiratory continued to advance its strategy in antiviral and respiratory disease drug development, with a particular emphasis on strengthening governance and business development capabilities.

The company appointed Melissa Faris as an independent non-executive director to its board, bringing decades of experience in respiratory and immunology business development. Faris currently serves as Chief Business Officer at U.K.-based OMass Therapeutics and previously spent about 20 years at GSK in senior roles spanning clinical development and business development.

Her background includes overseeing respiratory and immunology medicine programs from Phase 1 through registration and launch, as well as leading immunology business development at GSK. This breadth of experience in portfolio strategy, clinical development, and dealmaking is expected to support ENA Respiratory’s partnering, licensing, and commercialization efforts.

The appointment comes as ENA Respiratory advances INNA-051, its lead antiviral host defence enhancer, through clinical development. INNA-051 is a once-weekly nasal dry powder that targets TLR2/6 to boost local innate immunity, aiming to reduce the burden and complications of viral respiratory infections in high-risk groups such as older adults, patients with chronic conditions, and frontline workers.

The program has already shown encouraging data in a Phase IIa influenza human challenge study, including accelerated viral clearance and robust interferon responses, supporting its potential as a virus-agnostic prophylactic platform. ENA Respiratory is backed by investors including Brandon Capital, Flu Lab, the Gates Foundation, Minderoo Foundation, Stoic Venture Capital, and Uniseed, and benefits from U.S. Government contracts and a partnership with the US COPD Foundation.

These relationships, combined with the enhanced board-level expertise in business development, may help the company secure additional collaborations and funding as it positions INNA-051 for broader clinical and commercial opportunities. Overall, the week marked a governance and strategic milestone for ENA Respiratory as it aligns leadership capabilities with the growing ambitions of its antiviral and respiratory pipeline.